← Therapy pipeline
Investigational · Obesity development

Pemvidutide

Altimmune

GLP-1/glucagon agonist; current Phase 3 work centers on MASH.

GLP-1glucagon
Other study areas
Liver disease (MASLD / MASH)Alcohol-associated liver diseaseAlcohol use disorder
Selected program areas, not approvals. See the full profile for individual trials.
Obesity stagePhase 2Updated as of November 2026
SponsorAltimmune
TargetsGLP-1 + glucagon
RouteInjection
DevelopmentObesity-specific
01 / Evidence

Selected study results

MOMENTUMMean body-weight reductionBody weight decreased 15.6% · 48 weeks · Phase 2
Phase 2 · Injection · Sponsor-reported numerical results

Mean body-weight reduction · 48 weeks

Study focus: Weight management without type 2 diabetes

Investigational regimen
15.6%
Placebo / comparator
2.2%

Adults with obesity or overweight and a weight-related complication, without diabetes · 2.4 mg once weekly vs placebo · Trial N=391 · Sponsor topline; see source for missing-data methods. Results & methods ↗

Obesity evidence remains Phase 2; later MASH development does not change the obesity phase.

RECLAIMChange from baseline in heavy drinking days per weekHeavy drinking days decreased 4.2 days/week · 24 weeks · Phase 2
Phase 2 · Injection · Sponsor-reported numerical results

Change from baseline in heavy drinking days per week · 24 weeks

Study focus: Alcohol-use-disorder outcomes

The placebo-adjusted difference was 1.45 fewer heavy-drinking days per week (p=0.0014).

Pemvidutide 2.4 mg once weekly
4.2 days/week fewer
Placebo
2.8 days/week fewer

Adults with alcohol use disorder and BMI >25 kg/m² · 2.4 mg once weekly vs placebo · Trial N=100 · Sponsor-reported least-squares means; topline, pending peer-reviewed publication. Results & methods ↗

Additional results or analyses from this same study
  • Same study · key secondary outcomesTwo-level WHO risk-drinking reduction: 64.4% vs 34.8%; zero heavy-drinking days during weeks 21–24: 42.2% vs 17.4%.
  • Same study · weight outcomeAt 24 weeks, the placebo-adjusted difference in body-weight change was 9.1%.

Sponsor topline data, not yet peer reviewed.

IMPACT · MASH histology and follow-upParticipants with MASH resolution without worsening of fibrosisParticipants with MASH resolution without worsening of fibrosis: 59.1% · 24 weeks; 48-week follow-up below · Phase 2b
Phase 2b · Injection · Sponsor-reported week-24 histology and peer-reviewed week-48 follow-up

Participants with MASH resolution without worsening of fibrosis · 24 weeks; 48-week follow-up below

Study focus: Liver outcomes (MASH)

Pemvidutide 1.2 mg
59.1%
Placebo
19.1%

Adults with biopsy-confirmed MASH and F2/F3 fibrosis, with or without diabetes · 1.2 mg once weekly vs placebo; 1.8 mg arm noted below · Trial N=212 · Displayed week-24 histology estimates are from the sponsor report, which counted missing biopsies as nonresponse.. Results & methods ↗ · Publication ↗

Additional results or analyses from this same study
  • Other dose and fibrosis endpoint · 24 weeksAt 1.8 mg, MASH resolution was 52.1% versus 19.1% with placebo. Fibrosis improvement without worsening of MASH was 31.8% (1.2 mg) and 34.5% (1.8 mg), versus 25.9%; neither fibrosis comparison was statistically significant.
  • Follow-up · 48 weeksAt 48 weeks, the combined threshold of ELF reduction ≥0.5 and liver-stiffness reduction ≥30% was met by 32.4% with 1.8 mg versus 3.2% with placebo. The sponsor also reported additional weight and metabolic findings; these are secondary and noninvasive outcomes. Follow-up source ↗
  • Peer-reviewed week-48 follow-up · liver fatIn the intention-to-treat analysis of 212 randomized adults with biopsy-confirmed MASH and F2 or F3 fibrosis, estimated mean relative change in liver fat was −45.2% with 1.2 mg, −54.7% with 1.8 mg and −8.2% with placebo. These were secondary, non-invasive outcomes. The study collected no week-48 biopsies. Follow-up source ↗

Fibrosis improvement was not statistically significant at 24 weeks. Later noninvasive markers do not establish histologic fibrosis improvement.

Each graphic shows results within one study. Alternate analyses and follow-up from that study are labeled together. Study averages are not individual predictions or cross-trial comparisons.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIP—
GCGglucagonTargeted
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

InjectionOnce weekly
Phase 2MOMENTUM obesity study completed
Milestone → next

Latest: Phase 2 obesity evidence is available; Phase 3 development is now focused on MASH, with Phase 2 AUD and ALD programs also represented.

Next: Phase 3 MASH and Phase 2 alcohol-related liver disease outcomes. Published obesity results remain Phase 2 evidence.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 2 studies1 record

Phase 2

MOMENTUM

Weight management
Study: CompletedResults: Sponsor results shown aboveStatus reviewed September 2026

48-week obesity trial in adults without diabetes; completed, with sponsor-reported results. No registry identifier was confirmed in the primary source.

Related conditions and outcomes

Phase 3 studies1 record

Phase 3

PERFORMA

Liver outcomes (MASH)
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Global trial in biopsy-confirmed MASH; initiated August 2026. This is liver-disease development, not Phase 3 obesity development.

Phase 2 studies3 records

Phase 2b

IMPACT

Liver outcomes (MASH)
Study: CompletedResults: Week-24 sponsor estimates and published week-48 results shown aboveStatus reviewed November 2026

Biopsy-confirmed MASH with F2/F3 fibrosis. Histology was assessed at week 24. The published week-48 results describe secondary non-invasive measures.

Phase 2

RECLAIM

Alcohol use disorder
Study: CompletedResults: Sponsor results shown aboveStatus reviewed November 2026

Alcohol use disorder in adults with obesity or overweight; completed, with positive sponsor topline results reported in July 2026.

Phase 2

RESTORE

Liver outcomes (alcohol-associated liver disease)
Study: OngoingResults: No registry results posted yetStatus reviewed November 2026

Alcohol-associated liver disease; active Phase 2 study.